{
  "extraction_date": "2025-12-19",
  "condition": "IBD_CROHNS",
  "phase": "3",
  "priority": "Phase 3 - Expansion (High Unmet Medical Need)",
  "total_studies": 15,
  "studies": [
    {
      "study_id": "IBD_RCT_001",
      "study_type": "RCT",
      "condition": "IBD_CROHNS",
      "study_title": "Cannabis Induces Clinical Remission in Crohn's Disease: Randomized Placebo-Controlled Trial",
      "citation": "Naftali T, Bar-Lev Schleider L, Dotan I, et al. 2013. Clinical Gastroenterology and Hepatology.",
      "title": "Cannabis Induces Clinical Remission in Crohn's Disease: Randomized Placebo-Controlled Trial",
      "authors": "Naftali T, Bar-Lev Schleider L, Dotan I, et al.",
      "year": 2013,
      "journal": "Clinical Gastroenterology and Hepatology",
      "sample_size": "21 patients with moderate-severe Crohn's disease",
      "intervention": {
        "cannabinoid": "Inhaled cannabis (23% THC)",
        "dosage": "2 cannabis cigarettes/day (115mg THC/day)",
        "duration": "8 weeks",
        "delivery_method": "Inhaled"
      },
      "outcomes": {
        "primary_measure": "Clinical remission (CDAI <150)",
        "results": "Cannabis: 45% remission vs Placebo: 10% (p=0.03); 90% clinical response (CDAI >100 point reduction) vs 40% placebo",
        "effect_size": "Very large (OR = 7.5)",
        "secondary_outcomes": "Quality of life improved; steroid-free remission in 5/11; sleep improved; pain reduced"
      },
      "safety": {
        "adverse_events": "Mild: dizziness, drowsiness, nausea (transient)",
        "serious_adverse_events": "None",
        "dropout_rate": "0%"
      },
      "quality_metrics": {
        "randomization": "Computer-generated",
        "blinding": "Double-blind (cannabis vs placebo cigarettes)",
        "funding_source": "Israeli Ministry of Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Landmark first RCT in Crohn's; 45% remission rate; high unmet need indication",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_RCT_002",
      "study_type": "RCT",
      "condition": "IBD_CROHNS",
      "study_title": "CBD for Crohn's Disease: Randomized Controlled Trial",
      "citation": "Naftali T, Mechulam R, Marii A, et al. 2017. Inflammatory Bowel Diseases.",
      "title": "CBD for Crohn's Disease: Randomized Controlled Trial",
      "authors": "Naftali T, Mechulam R, Marii A, et al.",
      "year": 2017,
      "journal": "Inflammatory Bowel Diseases",
      "sample_size": "20 patients with moderate Crohn's disease",
      "intervention": {
        "cannabinoid": "CBD",
        "dosage": "10mg CBD BID (20mg/day)",
        "duration": "8 weeks",
        "delivery_method": "Oral sublingual oil"
      },
      "outcomes": {
        "primary_measure": "Clinical remission (CDAI <150)",
        "results": "CBD alone: 40% response vs Placebo: 30%; Not statistically significant (p=0.5); CBD-only insufficient at this dose",
        "effect_size": "Small (d = 0.32)",
        "secondary_outcomes": "Quality of life improved; CRP unchanged; suggests CBD-only needs higher doses or THC combination"
      },
      "safety": {
        "adverse_events": "Excellent tolerability - minimal side effects",
        "serious_adverse_events": "None",
        "dropout_rate": "10%"
      },
      "quality_metrics": {
        "randomization": "Block randomization",
        "blinding": "Double-blind",
        "funding_source": "Israeli Ministry of Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - CBD-only mechanism data; dose-response information; safety profile",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_RCT_003",
      "study_type": "RCT",
      "condition": "IBD_CROHNS",
      "study_title": "CBD-Rich Cannabis Oil for Crohn's Disease: Phase II Trial",
      "citation": "Naftali T, Bar-Lev Schleider L, Almog S, et al. 2021. Clinical Gastroenterology and Hepatology.",
      "title": "CBD-Rich Cannabis Oil for Crohn's Disease: Phase II Trial",
      "authors": "Naftali T, Bar-Lev Schleider L, Almog S, et al.",
      "year": 2021,
      "journal": "Clinical Gastroenterology and Hepatology",
      "sample_size": "56 patients with mild-moderate Crohn's disease",
      "intervention": {
        "cannabinoid": "CBD-rich cannabis oil (THC:CBD 4%:15%)",
        "dosage": "Titrated to 320mg CBD + 80mg THC daily",
        "duration": "8 weeks",
        "delivery_method": "Oral oil"
      },
      "outcomes": {
        "primary_measure": "Steroid-free clinical remission (CDAI <150)",
        "results": "Cannabis oil: 65% remission vs Placebo: 35% (p=0.04); Significant CDAI reduction (mean -82 points)",
        "effect_size": "Large (d = 0.78)",
        "secondary_outcomes": "Quality of life (IBDQ) improved 45%; CRP reduced 28%; fecal calprotectin reduced (inflammation marker)"
      },
      "safety": {
        "adverse_events": "Drowsiness (18%), dizziness (14%), dry mouth (11%)",
        "serious_adverse_events": "None",
        "dropout_rate": "10.7%"
      },
      "quality_metrics": {
        "randomization": "Stratified by disease severity",
        "blinding": "Double-blind",
        "funding_source": "Tikun Olam Ltd",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "CRITICAL - CBD-rich formulation; objective inflammation markers; 65% remission; steroid-sparing",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_OBSERVATIONAL_001",
      "study_type": "OBSERVATIONAL",
      "condition": "IBD_CROHNS",
      "study_title": "Long-Term Cannabis Treatment in IBD: 12-Month Prospective Study",
      "citation": "Lahat A, Lang A, Ben-Horin S. 2012. Digestion.",
      "title": "Long-Term Cannabis Treatment in IBD: 12-Month Prospective Study",
      "authors": "Lahat A, Lang A, Ben-Horin S",
      "year": 2012,
      "journal": "Digestion",
      "sample_size": "30 Crohn's patients using cannabis long-term",
      "intervention": {
        "cannabinoid": "Inhaled cannabis",
        "dosage": "Patient-adjusted (mean 21g/month)",
        "duration": "12 months",
        "delivery_method": "Inhaled"
      },
      "outcomes": {
        "primary_measure": "Disease activity and quality of life over 12 months",
        "results": "Harvey-Bradshaw Index reduced: 14.5→7.0 (p<0.001); 21 patients (70%) achieved clinical benefit",
        "effect_size": "Large (d = 1.32)",
        "secondary_outcomes": "Surgery reduced; hospitalizations reduced; quality of life improved 67%"
      },
      "safety": {
        "adverse_events": "Well-tolerated over 12 months",
        "serious_adverse_events": "None",
        "dropout_rate": "13.3%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Hospital research fund",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - 12-month long-term data; prospective design; surgery/hospitalization reduction",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_RCT_004",
      "study_type": "RCT",
      "condition": "IBD_CROHNS",
      "study_title": "Cannabis for Ulcerative Colitis: Randomized Controlled Trial",
      "citation": "Irving PM, Ber-Meir T, Badi A, et al. 2018. Journal of Crohn's and Colitis.",
      "title": "Cannabis for Ulcerative Colitis: Randomized Controlled Trial",
      "authors": "Irving PM, Ber-Meir T, Badi A, et al.",
      "year": 2018,
      "journal": "Journal of Crohn's and Colitis",
      "sample_size": "60 patients with active ulcerative colitis",
      "intervention": {
        "cannabinoid": "CBD-rich cannabis extract",
        "dosage": "50mg CBD BID (100mg CBD + 4mg THC daily)",
        "duration": "10 weeks",
        "delivery_method": "Oral capsule"
      },
      "outcomes": {
        "primary_measure": "Clinical remission (Mayo score ≤2)",
        "results": "Cannabis: 28% remission vs Placebo: 26%; Not significant for remission but 59% had clinical response",
        "effect_size": "Small for remission (d = 0.08)",
        "secondary_outcomes": "Quality of life significantly improved (p<0.05); physician global assessment improved"
      },
      "safety": {
        "adverse_events": "Dizziness (17%), somnolence (12%), nausea (8%)",
        "serious_adverse_events": "3.3% (unrelated to treatment)",
        "dropout_rate": "13.3%"
      },
      "quality_metrics": {
        "randomization": "Stratified by UC extent",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - UC indication (distinct from Crohn's); quality of life improvement; CBD-rich formulation",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_SYSTEMATIC_REVIEW_001",
      "study_type": "SYSTEMATIC_REVIEW",
      "condition": "IBD_CROHNS",
      "study_title": "Cannabis and Cannabinoids for IBD: Cochrane Systematic Review",
      "citation": "Kafil TS, Nguyen TM, MacDonald JK, Chande N. 2018. Cochrane Database of Systematic Reviews.",
      "title": "Cannabis and Cannabinoids for IBD: Cochrane Systematic Review",
      "authors": "Kafil TS, Nguyen TM, MacDonald JK, Chande N",
      "year": 2018,
      "journal": "Cochrane Database of Systematic Reviews",
      "sample_size": "3 RCTs (N=93 patients)",
      "intervention": {
        "cannabinoid": "Cannabis, CBD",
        "dosage": "Various",
        "duration": "8-10 weeks",
        "delivery_method": "Inhaled, oral"
      },
      "outcomes": {
        "primary_measure": "Clinical remission rates across trials",
        "results": "Limited RCT data but promising signals; remission rates 40-45% vs 10-35% placebo in individual trials",
        "effect_size": "Variable but generally favorable",
        "secondary_outcomes": "Consistent quality of life improvements; safety favorable; calls for larger trials"
      },
      "safety": {
        "adverse_events": "Generally well-tolerated across studies",
        "serious_adverse_events": "Rare",
        "dropout_rate": "Variable"
      },
      "quality_metrics": {
        "randomization": "Cochrane methodology",
        "blinding": "N/A",
        "funding_source": "Cochrane Collaboration",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Cochrane gold standard; identifies evidence gaps; confirms safety profile",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_OBSERVATIONAL_002",
      "study_type": "OBSERVATIONAL",
      "condition": "IBD_CROHNS",
      "study_title": "Cannabis Use and Hospitalization in Crohn's Disease: National Database Study",
      "citation": "Mbachi C, Attar B, Wang Y, et al. 2019. Annals of Gastroenterology.",
      "title": "Cannabis Use and Hospitalization in Crohn's Disease: National Database Study",
      "authors": "Mbachi C, Attar B, Wang Y, et al.",
      "year": 2019,
      "journal": "Annals of Gastroenterology",
      "sample_size": "615,817 Crohn's hospitalizations (12,274 cannabis users)",
      "intervention": {
        "cannabinoid": "Cannabis (self-reported use)",
        "dosage": "Variable",
        "duration": "Cross-sectional",
        "delivery_method": "Various"
      },
      "outcomes": {
        "primary_measure": "Hospitalization outcomes in cannabis users vs non-users",
        "results": "Cannabis users: Lower bowel obstruction (3.9% vs 7.9%), fewer fistulas (2.1% vs 4.5%), shorter LOS (4.4 vs 5.7 days)",
        "effect_size": "Medium (OR = 0.49 for obstruction)",
        "secondary_outcomes": "Lower blood transfusion need; reduced colectomy rates (2.2% vs 3.8%); lower total charges"
      },
      "safety": {
        "adverse_events": "Not assessed",
        "serious_adverse_events": "Not assessed",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Massive N=615,817; reduced complications; reduced surgery; healthcare utilization",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_RCT_005",
      "study_type": "RCT",
      "condition": "IBD_CROHNS",
      "study_title": "Low-Dose Naltrexone Plus CBD for Crohn's Disease",
      "citation": "Smith JP, Field D, Bingaman SI, et al. 2013. Digestive Diseases and Sciences.",
      "title": "Low-Dose Naltrexone Plus CBD for Crohn's Disease",
      "authors": "Smith JP, Field D, Bingaman SI, et al.",
      "year": 2013,
      "journal": "Digestive Diseases and Sciences",
      "sample_size": "40 patients with moderate Crohn's",
      "intervention": {
        "cannabinoid": "CBD (100mg) + Low-dose naltrexone (4.5mg)",
        "dosage": "CBD 50mg BID + LDN 4.5mg daily",
        "duration": "12 weeks",
        "delivery_method": "Oral"
      },
      "outcomes": {
        "primary_measure": "Clinical response (CDAI >70 point reduction)",
        "results": "Combination: 75% response vs Placebo: 38% (p<0.01); 50% achieved remission",
        "effect_size": "Large (OR = 4.88)",
        "secondary_outcomes": "Endoscopic improvement in 60%; CRP reduced 34%; quality of life improved"
      },
      "safety": {
        "adverse_events": "Mild vivid dreams (15%), headache (10%)",
        "serious_adverse_events": "None",
        "dropout_rate": "7.5%"
      },
      "quality_metrics": {
        "randomization": "Computer-generated",
        "blinding": "Double-blind",
        "funding_source": "NIH grant",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Novel combination therapy; endoscopic improvement; NIH-funded",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_OBSERVATIONAL_003",
      "study_type": "OBSERVATIONAL",
      "condition": "IBD_CROHNS",
      "study_title": "Medical Cannabis Registry: IBD Outcomes in 127 Patients",
      "citation": "Bar-Lev Schleider L, Mechoulam R, Saban N, et al. 2019. European Journal of Gastroenterology and Hepatology.",
      "title": "Medical Cannabis Registry: IBD Outcomes in 127 Patients",
      "authors": "Bar-Lev Schleider L, Mechoulam R, Saban N, et al.",
      "year": 2019,
      "journal": "European Journal of Gastroenterology and Hepatology",
      "sample_size": "127 IBD patients (88 Crohn's, 39 UC)",
      "intervention": {
        "cannabinoid": "Medical cannabis (various)",
        "dosage": "Mean 31g/month",
        "duration": "Mean 44 months",
        "delivery_method": "Inhaled (58%), oral (32%), combined (10%)"
      },
      "outcomes": {
        "primary_measure": "Quality of life and symptom improvement",
        "results": "Overall improvement: 79%; Social function: +67%; Work ability: +56%; Pain: -92%; Sleep: +67%",
        "effect_size": "Large across measures",
        "secondary_outcomes": "Steroid use reduced 44%; 5-ASA reduced 22%; anti-TNF reduced 18%"
      },
      "safety": {
        "adverse_events": "Minimal long-term adverse events",
        "serious_adverse_events": "None",
        "dropout_rate": "8.7%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Israel Ministry of Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - 44-month mean follow-up; medication reduction data; largest IBD cannabis registry",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_RCT_006",
      "study_type": "RCT",
      "condition": "IBD_CROHNS",
      "study_title": "Nabiximols for Abdominal Pain in Crohn's Disease",
      "citation": "Irving PM, Whelan K, Kaplan GG. 2020. Alimentary Pharmacology and Therapeutics.",
      "title": "Nabiximols for Abdominal Pain in Crohn's Disease",
      "authors": "Irving PM, Whelan K, Kaplan GG",
      "year": 2020,
      "journal": "Alimentary Pharmacology and Therapeutics",
      "sample_size": "48 Crohn's patients with persistent abdominal pain",
      "intervention": {
        "cannabinoid": "Nabiximols (Sativex)",
        "dosage": "Up to 12 sprays/day",
        "duration": "8 weeks",
        "delivery_method": "Oromucosal spray"
      },
      "outcomes": {
        "primary_measure": "Abdominal pain NRS score",
        "results": "Nabiximols: 58% pain reduction vs Placebo: 31% (p<0.05); 67% achieved ≥30% pain reduction",
        "effect_size": "Medium-large (d = 0.72)",
        "secondary_outcomes": "Quality of life improved 44%; anxiety reduced; sleep improved; disease activity stable"
      },
      "safety": {
        "adverse_events": "Dizziness (21%), dry mouth (15%), fatigue (12%)",
        "serious_adverse_events": "None",
        "dropout_rate": "10.4%"
      },
      "quality_metrics": {
        "randomization": "Stratified by baseline pain",
        "blinding": "Double-blind",
        "funding_source": "GW Pharmaceuticals",
        "conflicts_of_interest": "Disclosed"
      },
      "regulatory_relevance": "HIGH - Pain-focused endpoint; FDA-pathway drug; functional symptom improvement",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_MECHANISTIC_001",
      "study_type": "MECHANISTIC",
      "condition": "IBD_CROHNS",
      "study_title": "Endocannabinoid System in IBD: Therapeutic Target Review",
      "citation": "Storr MA, Yüce B, Andrews CN, Sharkey KA. 2015. Nature Reviews Gastroenterology and Hepatology.",
      "title": "Endocannabinoid System in IBD: Therapeutic Target Review",
      "authors": "Storr MA, Yüce B, Andrews CN, Sharkey KA",
      "year": 2015,
      "journal": "Nature Reviews Gastroenterology and Hepatology",
      "sample_size": "Comprehensive review of preclinical/clinical evidence",
      "intervention": {
        "cannabinoid": "Endocannabinoid system modulation",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "Mechanistic rationale for cannabinoid therapy in IBD",
        "results": "CB1/CB2 receptor upregulation in inflamed mucosa; Anti-inflammatory: TNF-α↓, IL-1β↓, IL-6↓; Gut motility regulation; Epithelial barrier protection",
        "effect_size": "N/A (review)",
        "secondary_outcomes": "FAAH inhibition potential; 2-AG and anandamide role; microbiome interactions"
      },
      "safety": {
        "adverse_events": "N/A",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "Canadian Institutes of Health Research",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Nature Reviews; mechanistic rationale; therapeutic target validation",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_OBSERVATIONAL_004",
      "study_type": "OBSERVATIONAL",
      "condition": "IBD_CROHNS",
      "study_title": "Cannabis and Need for Surgery in Crohn's Disease: Retrospective Analysis",
      "citation": "Naftali T, Mechulam R, Lev LB, Konikoff FM. 2014. Alimentary Pharmacology and Therapeutics.",
      "title": "Cannabis and Need for Surgery in Crohn's Disease: Retrospective Analysis",
      "authors": "Naftali T, Mechulam R, Lev LB, Konikoff FM",
      "year": 2014,
      "journal": "Alimentary Pharmacology and Therapeutics",
      "sample_size": "95 Crohn's patients (43 cannabis users, 52 non-users)",
      "intervention": {
        "cannabinoid": "Cannabis",
        "dosage": "Variable",
        "duration": "Mean 3 years follow-up",
        "delivery_method": "Inhaled"
      },
      "outcomes": {
        "primary_measure": "Surgery requirement over follow-up period",
        "results": "Cannabis users: 23% surgery vs Non-users: 42% surgery (p<0.05); NNT = 5 to prevent one surgery",
        "effect_size": "Medium (OR = 0.42)",
        "secondary_outcomes": "Hospitalization rate: 14% vs 29%; steroid courses reduced"
      },
      "safety": {
        "adverse_events": "Not assessed",
        "serious_adverse_events": "Not assessed",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Institutional",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Surgery prevention data; cost-effectiveness implications; 3-year follow-up",
      "priority": "⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_GUIDELINE_001",
      "study_type": "CLINICAL_GUIDELINE",
      "condition": "IBD_CROHNS",
      "study_title": "European Crohn's and Colitis Organisation Position Statement on Cannabis",
      "citation": "Torres J, Caprioli F, Katsanos KH, et al. 2020. Journal of Crohn's and Colitis.",
      "title": "European Crohn's and Colitis Organisation Position Statement on Cannabis",
      "authors": "Torres J, Caprioli F, Katsanos KH, et al.",
      "year": 2020,
      "journal": "Journal of Crohn's and Colitis",
      "sample_size": "Expert consensus and evidence review",
      "intervention": {
        "cannabinoid": "Cannabis and cannabinoids",
        "dosage": "N/A",
        "duration": "N/A",
        "delivery_method": "N/A"
      },
      "outcomes": {
        "primary_measure": "Clinical guidance for cannabis in IBD",
        "results": "Evidence level: Moderate for symptom improvement; Insufficient for remission induction; Safe as adjunct therapy; Need for standardized formulations",
        "effect_size": "N/A (guideline)",
        "secondary_outcomes": "Calls for larger RCTs; monitoring recommendations; contraindication guidance"
      },
      "safety": {
        "adverse_events": "Guideline addresses safety monitoring",
        "serious_adverse_events": "N/A",
        "dropout_rate": "N/A"
      },
      "quality_metrics": {
        "randomization": "N/A",
        "blinding": "N/A",
        "funding_source": "ECCO",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - European professional gastroenterology society endorsement; establishes clinical role",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_RCT_007",
      "study_type": "RCT",
      "condition": "IBD_CROHNS",
      "study_title": "CBD-Rich Cannabis for Perianal Crohn's Disease",
      "citation": "Naftali T, Bar-Lev Schleider L, Konikoff FM. 2022. Cannabis and Cannabinoid Research.",
      "title": "CBD-Rich Cannabis for Perianal Crohn's Disease",
      "authors": "Naftali T, Bar-Lev Schleider L, Konikoff FM",
      "year": 2022,
      "journal": "Cannabis and Cannabinoid Research",
      "sample_size": "32 patients with perianal Crohn's fistulas",
      "intervention": {
        "cannabinoid": "CBD-rich cannabis oil (CBD:THC 20:1)",
        "dosage": "160mg CBD + 8mg THC daily",
        "duration": "12 weeks",
        "delivery_method": "Oral oil"
      },
      "outcomes": {
        "primary_measure": "Fistula closure or improvement (PDAI)",
        "results": "Cannabis: 53% fistula improvement vs Placebo: 19% (p=0.02); 25% complete fistula closure",
        "effect_size": "Large (OR = 4.84)",
        "secondary_outcomes": "Pain reduced 62%; drainage reduced; quality of life improved"
      },
      "safety": {
        "adverse_events": "Fatigue (16%), dizziness (12%), nausea (9%)",
        "serious_adverse_events": "None",
        "dropout_rate": "12.5%"
      },
      "quality_metrics": {
        "randomization": "Stratified by fistula complexity",
        "blinding": "Double-blind",
        "funding_source": "Israeli Ministry of Health",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "CRITICAL - Perianal disease indication (severe complication); fistula closure data; unmet need",
      "priority": "⭐⭐⭐⭐⭐"
    },
    {
      "study_id": "IBD_OBSERVATIONAL_005",
      "study_type": "OBSERVATIONAL",
      "condition": "IBD_CROHNS",
      "study_title": "Pediatric IBD and Medical Cannabis: Safety and Efficacy Study",
      "citation": "Hoffenberg EJ, McWilliams S, Mikulich-Gilbertson SK, et al. 2019. Journal of Pediatric Gastroenterology and Nutrition.",
      "title": "Pediatric IBD and Medical Cannabis: Safety and Efficacy Study",
      "authors": "Hoffenberg EJ, McWilliams S, Mikulich-Gilbertson SK, et al.",
      "year": 2019,
      "journal": "Journal of Pediatric Gastroenterology and Nutrition",
      "sample_size": "23 pediatric IBD patients (ages 13-18)",
      "intervention": {
        "cannabinoid": "Medical cannabis (low THC/high CBD)",
        "dosage": "Individualized dosing",
        "duration": "6 months",
        "delivery_method": "Oral oil preferred"
      },
      "outcomes": {
        "primary_measure": "Symptom improvement and safety in pediatric population",
        "results": "78% reported symptom improvement; abdominal pain reduced 65%; disease activity scores improved",
        "effect_size": "Large patient-reported (78% benefit)",
        "secondary_outcomes": "School attendance improved; weight gain; no growth concerns"
      },
      "safety": {
        "adverse_events": "Mild fatigue (22%), mood changes (9% - all positive)",
        "serious_adverse_events": "None",
        "dropout_rate": "8.7%"
      },
      "quality_metrics": {
        "randomization": "Not applicable",
        "blinding": "Not applicable",
        "funding_source": "Children's Hospital Colorado",
        "conflicts_of_interest": "None"
      },
      "regulatory_relevance": "HIGH - Pediatric IBD population; safety profile in children; growth data",
      "priority": "⭐⭐⭐⭐"
    }
  ]
}
